COYA
Price:
$5.41
Market Cap:
$90.39M
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination f...[Read more]
Industry
Biotechnology
IPO Date
2022-12-29
Stock Exchange
NASDAQ
Ticker
COYA
According to Coya Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -31.59%. This represents a change of 286.03% compared to the average of -8.18% of the last 4 quarters.
The mean historical ROE of Coya Therapeutics, Inc. over the last ten years is 2.49%. The current -31.59% ROE has changed -1369.08% with respect to the historical average. Over the past ten years (40 quarters), COYA's ROE was at its highest in in the June 2022 quarter at 242.68%. The ROE was at its lowest in in the March 2022 quarter at -46.83%.
Average
2.49%
Median
-15.62%
Minimum
-133.66%
Maximum
174.87%
Discovering the peaks and valleys of Coya Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.41%
Maximum Annual ROE = 174.87%
Minimum Annual Increase = -230.83%
Minimum Annual ROE = -133.66%
Year | ROE | Change |
---|---|---|
2023 | -22.42% | -112.82% |
2022 | 174.87% | -230.83% |
2021 | -133.66% | 1.41% |
The current ROE of Coya Therapeutics, Inc. (COYA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.26%
5-year avg
2.49%
10-year avg
2.49%
Coya Therapeutics, Inc.’s ROE is greater than Cue Biopharma, Inc. (-156.38%), greater than Lantern Pharma Inc. (-56.90%), less than Fennec Pharmaceuticals Inc. (31.99%), less than Eliem Therapeutics, Inc. (0%), greater than Acumen Pharmaceuticals, Inc. (-32.99%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), less than Galera Therapeutics, Inc. (14.34%), greater than Cognition Therapeutics, Inc. (-150.93%), greater than TFF Pharmaceuticals, Inc. (-310.17%), greater than TScan Therapeutics, Inc. (-58.72%), greater than Dermata Therapeutics, Inc. (-247.40%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Sutro Biopharma, Inc. (-97.01%), less than Opthea Limited (398.06%), greater than HilleVax, Inc. (-67.27%), greater than Gain Therapeutics, Inc. (-203.91%), greater than aTyr Pharma, Inc. (-56.83%), greater than IN8bio, Inc. (-197.15%),
Company | ROE | Market cap |
---|---|---|
-156.38% | $62.96M | |
-56.90% | $33.54M | |
31.99% | $169.37M | |
0% | $342.68M | |
-32.99% | $108.14M | |
-88.42% | $186.88M | |
-32.76% | $488.40M | |
-22.40% | $1.27B | |
14.34% | $1.64M | |
-150.93% | $25.86M | |
-310.17% | $288.80K | |
-58.72% | $157.98M | |
-247.40% | $2.63M | |
-53.79% | $2.92B | |
-52.22% | $2.18B | |
-97.01% | $156.67M | |
398.06% | $4.46B | |
-67.27% | $93.39M | |
-203.91% | $41.64M | |
-56.83% | $131.12M | |
-197.15% | $17.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coya Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coya Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Coya Therapeutics, Inc.'s ROE?
How is the ROE calculated for Coya Therapeutics, Inc. (COYA)?
What is the highest ROE for Coya Therapeutics, Inc. (COYA)?
What is the 3-year average ROE for Coya Therapeutics, Inc. (COYA)?
What is the 5-year average ROE for Coya Therapeutics, Inc. (COYA)?
How does the current ROE for Coya Therapeutics, Inc. (COYA) compare to its historical average?